Founded 2002 | ||
Signum Biosciences, Inc. is a biotechnology company in Monmouth Junction, NJ. It was founded in 2003 based on research done in the lab of Jeffry B. Stock, a professor at Princeton University, on compounds that can modulate protein phosphatase 2 (PP2). Gregory Stock, Stock's brother, served as the first CEO.
In 2008 Signum partnered with Rohto Pharmaceutical Co. of Japan to commercialize Signum's product, n-acetyl-s-farnsylcysteine (Arazine); that product was launched in Japan in 2010.
In 2011 Signum partnered with GlaxoSmithKline to develop drugs screened against PP2 for neurodegenerative diseases.
In 2011 Signum spun out a dermatology company, originally called Argyle Therapeutics but after 2012 called Signum Dermalogix. In 2012 Argyle licensed one of its compounds, SIG990, to Brickell Biotech for development as a drug to treat rosacea.
In 2015 Signum partnered with Nerium International to launch a dietary supplement called eicosanoyl-5-hydroxytryptamide (EHT). EHT is derived from coffee and inhibits demethylaton of the enzyme protein phosphatase 2 (PPP2CA; PP2A). EHT has shown neuroprotective effects in a mouse model of Parkinson's disease.